Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 13/20 | 0.69 |
| ▸ | BMPR1A | P36894 | 6/20 | 0.50 |
| ▸ | BMP4 | P12644 | 4/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 4/20 | 0.47 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.47 |
| ▸ | ACVR1B | P36896 | 4/20 | 0.47 |
| ▸ | KDR | P35968 | 4/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.47 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.47 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.46 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.46 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17448659 | 0.84 | ACVR1 (0.68) | ACVR1BMPR1ABMP4BMPR1BACVRL1 | |
| SCHEMBL24409653 | 0.82 | ACVR1 (0.70) | ACVR1BMPR1ABMP4BMPR1BACVRL1 | |
| SCHEMBL17442183 | 0.82 | ACVR1 (1.00) | ACVR1BMPR1ABMP4BMPR1BACVRL1 | |
| SCHEMBL17448643 | 0.81 | ACVR1 (0.64) | ACVR1BMPR1ABMP4BMPR1BACVRL1 | |
| SCHEMBL19110557 | 0.81 | ACVR1 (0.51) | ACVR1BMPR1ABMP4BMPR1BACVRL1 | |
| SCHEMBL23988780 | 0.81 | ACVR1 (0.70) | ACVR1BMPR1ABMP4BMPR1BACVRL1 | |
| SCHEMBL17448590 | 0.81 | ACVR1B (0.69) | ACVR1BMPR1ABMP4BMPR1BACVRL1 | |
| SCHEMBL17448665 | 0.80 | ACVR1 (0.75) | ACVR1BMPR1ABMP4BMPR1BACVRL1 | |
| SCHEMBL17448569 | 0.79 | ACVR1 (0.69) | ACVR1BMPR1ABMP4BMPR1BACVRL1 | |
| SCHEMBL17448611 | 0.79 | ACVR1 (0.55) | ACVR1BMPR1ABMP4BMPR1BACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022098812-A1 | METHODS OF TREATING IRON OVERLOAD | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | ACVR1 12/4885BMPR1A 7/4885BMP4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.